Date | Price Target | Rating | Analyst |
---|---|---|---|
7/1/2024 | Buy → Neutral | H.C. Wainwright | |
11/16/2022 | $44.00 | Buy → Neutral | B. Riley Securities |
1/24/2022 | $108.00 → $72.00 | Buy | B. Riley Securities |
7/20/2021 | $97.00 → $124.00 | Buy | HC Wainwright & Co. |
7/15/2021 | $100.00 | Overweight → Neutral | Cantor Fitzgerald |
7/7/2021 | $80.00 → $190.00 | Buy | Maxim Group |
6/23/2021 | $78.00 → $111.00 | Buy | B. Riley Securities |
AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today announced it has concluded its search for a Chief Executive Officer and that its Board of Directors has named Richard (Rick) Barry as CEO. Mr. Barry has served as a director of Cassava since June 2021. On July 17 of this year, the Board appointed him Executive Chairman of the Board and the Company's principal executive officer and while undertaking a now completed search for a permanent CEO. In keeping with the company's pledge to follow good governance principles, the Company is separating the positions of CEO and Chairman by appointing Cla
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company's principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) investors that a lawsuit was filed on behalf of investors that purchased Cassava securities between August 18, 2022 and October 12, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investo
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 43.6% on an annualized basis producing an average annual return of 56.63%. Currently, Cassava Sciences has a market capitalization of $597.06 million. Buying $1000 In SAVA: If an investor had bought $1000 of SAVA stock 5 years ago, it would be worth $9,083.94 today based on a price of $12.45 for SAVA at the time of writing. Cassava Sciences's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automat
On Monday, Rick Barry, the executive chairman of Cassava Sciences Inc (NASDAQ:SAVA), wrote a letter to shareholders and employees. He said the company is in the final stages of testing its Alzheimer’s drug candidate, simufilam, with significant financial and emotional stakes. The company is conducting Phase 3 trials to demonstrate the drug’s efficacy and safety. Related: Alzheimer’s-Focused Cassava Sciences Faces Controversy as Key Collaborator Accused of Scientific Misconduct. These trials, costing hundreds of millions of dollars, are essential for determining if simufilam can significantly impact the lives of Alzheimer’s patients and their families. Cassava Sciences’ executi
Shares of CrowdStrike Holdings, Inc. (NASDAQ:CRWD) fell sharply during Monday’s session. Guggenheim analyst John Difucci downgraded the stock from Buy to Neutral, while BTIG analyst Gray Powell downgraded the stock from Buy to Neutral. CrowdStrike shares dipped over 11% on Friday after the company suffered a major outage impacting businesses around the world. Selective Insurance Group shares dipped 13.2% to $264.65 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares climbed 148% to $1.98 after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2. CareMa
8-K - CASSAVA SCIENCES INC (0001069530) (Filer)
8-K - CASSAVA SCIENCES INC (0001069530) (Filer)
8-K/A - CASSAVA SCIENCES INC (0001069530) (Filer)
AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it will hold a conference call on Thursday, August 8th at 8:30 a.m. Eastern Time. Event details follow:Date:Thursday, August 8thTime: 8:30 a.m. Eastern TimeAudio Webcast:https://www.CassavaSciences.com/company-presentationsOr Audio Webcast:https://edge.media-server.com/mmc/p/zjvmjjcr A replay of the audio webcast will also be available on the Company Presentations page of the Cassava Sciences' website for 90 days following the webcast. About Cassava Sciences, Inc.Cassava Sciences is a clinical-stage biotechnolo
$126.3 Million In Total Gross Proceeds from Warrant Distribution.Over 1,900 Patients with Alzheimer's Disease Are Randomized in Phase 3 Trials of Simufilam.Over 735 Patients Have Completed a Phase 3 Trial of Simufilam. AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million compared to a net loss of $24.3 million for the same period in 2023. Net cash used in operations was $19.1 million during the first quarter of 2024. Cash use for operations for the first half of 2024 is still expected to be $35 to $
Shareholders of Record Received Warrants to Purchase Shares of Common Stock Warrants Trade on Nasdaq Under the Ticker "SAVAW"Warrant Holders Who Choose to Exercise During an Early Period Will Receive an Additional 0.5 of a Common Share Per Warrant AUSTIN, Texas, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA) ("Cassava Sciences" or the "Company") today announced the completion of a previously announced distribution of warrants (the "Warrants") to its shareholders. The Warrants now trade on Nasdaq under the ticker SAVAW. Stockholders received four (4) Warrants for each ten (10) shares of the Company's common stock held as of December 22, 2023 (the "Record Da
SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)
SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)
SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)
H.C. Wainwright downgraded Cassava Sciences from Buy to Neutral
B. Riley Securities downgraded Cassava Sciences from Buy to Neutral and set a new price target of $44.00
B. Riley Securities reiterated coverage of Cassava Sciences with a rating of Buy and set a new price target of $72.00 from $108.00 previously
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
4 - CASSAVA SCIENCES INC (0001069530) (Issuer)
AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on Alzheimer's disease, today announced it has concluded its search for a Chief Executive Officer and that its Board of Directors has named Richard (Rick) Barry as CEO. Mr. Barry has served as a director of Cassava since June 2021. On July 17 of this year, the Board appointed him Executive Chairman of the Board and the Company's principal executive officer and while undertaking a now completed search for a permanent CEO. In keeping with the company's pledge to follow good governance principles, the Company is separating the positions of CEO and Chairman by appointing Cla
AUSTIN, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that it has been invited to present at the H.C. Wainwright 26th Annual Global Investment Conference, being held in New York. Rick Barry, Cassava's Executive Chairman, will join in a ‘fireside chat' with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C. Wainwright. Institutional investors who are registered for this conference may log into www.hcwevents.com to request a meeting with Cassava Sciences, pending availability. Event details follow: Date:Monday, September 9thTime:3:00pm
$207.3 Million in Cash and Cash Equivalents at June 30, 2024.Company in Advanced Discussions to Resolve SEC Investigation. $40 Million Estimated Loss Contingency Recorded in Q2 for Resolution.Conference Webcast Scheduled for Today at 8:30AM ET. AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a biotechnology company focused on a novel treatment for Alzheimer's disease, today reported financial results for the second quarter ended June 30, 2024. Net income was $6.2 million compared to a net loss of $26.4 million for the same period in 2023. Net cash used in operations was $37.4 million during the first half of 2024, consistent with previous guidance